Correlation Between Sarepta Therapeutics and Gilead Sciences

Can any of the company-specific risk be diversified away by investing in both Sarepta Therapeutics and Gilead Sciences at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Sarepta Therapeutics and Gilead Sciences into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Sarepta Therapeutics and Gilead Sciences, you can compare the effects of market volatilities on Sarepta Therapeutics and Gilead Sciences and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Sarepta Therapeutics with a short position of Gilead Sciences. Check out your portfolio center. Please also check ongoing floating volatility patterns of Sarepta Therapeutics and Gilead Sciences.

Diversification Opportunities for Sarepta Therapeutics and Gilead Sciences

-0.75

Correlation Coefficient

Sarepta Therapeutics  Gilead Sciences

Pay attention - limited upside

The 3 months correlation between Sarepta and Gilead is -0.75. Overlapping area represents the amount of risk that can be diversified away by holding Sarepta Therapeutics and Gilead Sciences in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Gilead Sciences and Sarepta Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Sarepta Therapeutics are associated (or correlated) with Gilead Sciences. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Gilead Sciences has no effect on the direction of Sarepta Therapeutics i.e., Sarepta Therapeutics and Gilead Sciences go up and down completely randomly.

Pair Corralation between Sarepta Therapeutics and Gilead Sciences

Given the investment horizon of 90 days Sarepta Therapeutics is expected to under-perform the Gilead Sciences. In addition to that, Sarepta Therapeutics is 2.76 times more volatile than Gilead Sciences. It trades about -0.16 of its total potential returns per unit of risk. Gilead Sciences is currently generating about 0.16 per unit of volatility. If you would invest  9,275  in Gilead Sciences on December 22, 2024 and sell it today you would earn a total of  1,433  from holding Gilead Sciences or generate 15.45% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Sarepta Therapeutics  vs.  Gilead Sciences

Sarepta Therapeutics

Risk-Adjusted Performance

Very Weak

Over the last 90 days Sarepta Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in April 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Gilead Sciences

Risk-Adjusted Performance

Good

Compared to the overall equity markets, risk-adjusted returns on investments in Gilead Sciences are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. In spite of rather unfluctuating essential indicators, Gilead Sciences exhibited solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Sarepta Therapeutics and Gilead Sciences

The main advantage of trading using opposite Sarepta Therapeutics and Gilead Sciences positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Sarepta Therapeutics position performs unexpectedly, Gilead Sciences can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Gilead Sciences will offset losses from the drop in Gilead Sciences' long position.

The idea behind Sarepta Therapeutics and Gilead Sciences pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.